Results 61 to 70 of about 6,306 (210)

Multiscale classification of heart failure phenotypes by unsupervised clustering of unstructured electronic medical record data

Scientific Reports, 2020
As a leading cause of death and morbidity, heart failure (HF) is responsible for a large portion of healthcare and disability costs worldwide. Current approaches to define specific HF subpopulations may fail to account for the diversity of etiologies ...
Tasha Nagamine, Brian Gillette, Alexey Pakhomov, John Kahoun, Hannah Mayer, Rolf Burghaus, Jörg Lippert, Mayur Saxena   +7 more
doaj   +1 more source

A minimal physiologically‐based pharmacokinetic modeling platform to predict intratumor exposure and receptor occupancy of an anti‐LAG‐3 monoclonal antibody

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 460-473, March 2025.
Abstract In oncology drug development, measuring drug concentrations at the tumor site and at the targeted receptor remains an ongoing challenge. Positron emission tomography (PET)‐imaging is a promising noninvasive method to quantify intratumor exposure of a radiolabeled drug (biodistribution data) and target saturation by treatment doses in vivo ...
Robin Michelet, Klas Petersson, Marc C. Huisman, C. Willemien Menke‐van der Houven van Oordt, Iris H. C. Miedema, Andrea Thiele, Ghazal Montaseri, Alejandro Pérez‐Pitarch, David Busse   +8 more
wiley   +1 more source

Opinion: The Pharmacometrics of Infectious Disease

CPT: Pharmacometrics & Systems Pharmacology, 2013
The application of pharmacometric principles to the treatment of infectious diseases must address important biological issues across the diversity of pathogenic organisms. Recent applications of pharmacometric tools in this therapeutic area have had important translational impact not only in drug development but on real‐world clinical practice.
Davies, G R, Hope, W, Khoo, S
openaire   +2 more sources

Disease Progression Mathematical Modeling With a Case Study on Hepatitis B Virus Infection

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 420-434, March 2025.
ABSTRACT Chronic Hepatitis B presents a significant health and socioeconomic burden. The risk of hepatocellular carcinoma remains elevated although treatments are available. Achieving an optimal treatment regimen necessitates a deep comprehension of the dynamic relationship between the virus and its host across disease states.
Clémence Boivin‐Champeaux, Nieves Velez de Mendizabal, Aksana Jones, Scott Balsitis, Stephan Schmidt, Justin S. Feigelman, Francine Johansson Azeredo   +6 more
wiley   +1 more source

Modeling of Disease Progression of Type 2 Diabetes Using Real‐World Data: Quantifying Competing Risks of Morbidity and Mortality

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 606-615, March 2025.
ABSTRACT Type 2 diabetes (T2D) is a progressive metabolic disorder that could be an underlying cause of long‐term complications that increase mortality. The assessment of the probability of such events could be essential for mortality risk management. This work aimed to establish a framework for risk predictions of macrovascular complications (MVC) and
Hanna Kunina, Stefan Franzén, Maria C. Kjellsson   +2 more
wiley   +1 more source

Optimizing Perioperative Management of Haemophilia B With rFIX‐FP: Pharmacokinetic Validation of the Hemoptidose Tool

Haemophilia, EarlyView.
Abstract Background Surgical management of haemophilia B requires precise factor IX replacement to ensure adequate haemostasis while optimizing factor consumption. Extended half‐life rFIX‐FP simplifies perioperative management but exhibits substantial pharmacokinetic variability.
Xavier Delavenne, Célia Vollard, Nicolas Drillaud, Sabine Castet, Nicolas Luyck, Emilie Hénin, Julien Denis‐Le Seve, Fabienne Volot, Brigitte Tardy, Stéphanie Désage, Benoît Guillet   +10 more
wiley   +1 more source

Pharmacokinetics of Moxidectin in Bare‐Nosed Wombats (Vombatus ursinus) After Intravenous, Sub‐Cutaneous and Transdermal Administration

Journal of Veterinary Pharmacology and Therapeutics, EarlyView.
ABSTRACT The anti‐parasitic drug moxidectin is a frontline treatment for sarcoptic mange in bare‐nosed wombats (Vombatus ursinus), a disease causing significant animal welfare issues and instances of local population declines. Despite widespread usage, knowledge of species‐specific pharmacokinetics of moxidectin in bare‐nosed wombats is still limited ...
E. K. Stott, L. F. Skerratt, T. Whittem, M. Leeming, K. Pillay, G. S. Doran, B. Gardner, M. Lynch, M. Klein, P. Holz, T. Chen, J. Hufschmid, A. P. Woodward   +12 more
wiley   +1 more source

From Executor to Orchestrator: The Pharmacology Scientist in the Age of Agentic AI

Clinical Pharmacology &Therapeutics, Volume 120, Issue 3, Page 648-662, September 2026.
Drug development productivity has not improved despite five decades of computational advancement, with the probability that a compound entering Phase I achieving regulatory approval remaining near 10%. Each automation wave increased throughput while leaving the interpretive bottleneck intact; scientists continued to formulate questions, evaluate ...
Michael McCoy, Matthew McCoy
wiley   +1 more source

Focused Update to International Consensus Recommendations for the Use of Prolonged‐Infusion Beta‐Lactam Antibiotics Among Severely Ill Adult Patients: Endorsed by the American College of Clinical Pharmacy, British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, Society of Critical Care Medicine, and Society of Infectious Diseases Pharmacists

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 46, Issue 9, September 2026.
ABSTRACT In 2023, international consensus recommendations suggested the use of prolonged‐infusion beta‐lactam antibiotics over short‐infusion dosing in severely ill adult patients to improve mortality or clinical cure, although the certainty of evidence was very low. With the availability of several new randomized controlled trials (RCTs), this focused
Lisa T. Hong, Alireza FakhriRavari, Marta Ulldemolins, Jason A. Roberts, Robert A. Bonomo, Marc H. Scheetz, on behalf of the Prolonged‐Infusion Beta‐Lactam Consensus Panel, Jacinda C. Abdul‐Mutakabbir, Mohammad H. Alshaer, Matteo Bassetti, Robert A. Bonomo, Kevin J. Downes, Alireza FakhriRavari, Mark Gilchrist, Lisa T. Hong, Jason A. Roberts, Marc H. Scheetz, Thomas Tängdén, Marta Ulldemolins, David C. Young   +19 more
wiley   +1 more source

Evaluation of adalimumab tapering regimens in children and adolescents with juvenile idiopathic arthritis in remission: a simulation study

Pediatric Rheumatology Online Journal
Background Adalimumab (ADM) in children with juvenile idiopathic arthritis (JIA) is usually dosed using fixed weight-based bands (label dosing: 20 mg for  9 mg/L further increased proportion with target exposure to 56–63% while keeping the proportion of ...
Dominic S. Bräm, Verena Gotta, Gilbert Koch, Klervi Golhen, Andreas Woerner, Andrew Atkinson, Johannes N. van den Anker, Marc Pfister, Tatjana Welzel   +8 more
doaj   +1 more source